{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T16:48:54Z","timestamp":1744390134306},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00108-021-01249-w","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T09:03:32Z","timestamp":1642151012000},"page":"143-154","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biologika bei Kollagenosen und Vaskulitiden"],"prefix":"10.1007","volume":"63","author":[{"given":"Bernhard","family":"Hellmich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg C.","family":"Henes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"1249_CR1","doi-asserted-by":"publisher","first-page":"e001020","DOI":"10.1136\/rmdopen-2019-001020","volume":"5","author":"AF Agueda","year":"2019","unstructured":"Agueda\u00a0AF, Monti\u00a0S, Luqmani\u00a0RA et\u00a0al (2019) Management of Takayasu arteritis: a\u00a0systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open 5:e1020. https:\/\/doi.org\/10.1136\/rmdopen-2019-001020","journal-title":"RMD Open"},{"key":"1249_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218710","author":"M Akiyama","year":"2020","unstructured":"Akiyama\u00a0M, Kaneko\u00a0Y, Takeuchi\u00a0T (2020) Tocilizumab for the treatment of polyarteritis nodosa: a\u00a0systematic literature review. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218710","journal-title":"Ann Rheum Dis"},{"key":"1249_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218599","author":"AN Baer","year":"2020","unstructured":"Baer\u00a0AN, Gottenberg\u00a0JE, Clair\u00a0StEW et al (2020) Efficacy and safety of abatacept in active primary Sjogren\u2019s syndrome: results of a\u00a0phase III, randomised, placebo-controlled trial. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218599","journal-title":"Ann Rheum Dis"},{"key":"1249_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/art.41943","author":"A Bettiol","year":"2021","unstructured":"Bettiol\u00a0A, Urban\u00a0ML, Dagna\u00a0L et\u00a0al (2021) Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a\u00a0European multicenter observational study. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41943","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/art.41534","volume":"73","author":"A Canzian","year":"2021","unstructured":"Canzian\u00a0A, Venhoff\u00a0N, Urban\u00a0ML et\u00a0al (2021) Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: data from a\u00a0European Collaborative Study. Arthritis Rheumatol 73:498\u2013503. https:\/\/doi.org\/10.1002\/art.41534","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/M19-3827","volume":"173","author":"P Charles","year":"2020","unstructured":"Charles\u00a0P, Perrodeau\u00a0E, Samson\u00a0M et al (2020) Long-term Rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 173:179\u2013187. https:\/\/doi.org\/10.7326\/M19-3827","journal-title":"Ann Intern Med"},{"key":"1249_CR7","doi-asserted-by":"publisher","first-page":"707104","DOI":"10.3389\/fmed.2021.707104","volume":"8","author":"F Chowdhury","year":"2021","unstructured":"Chowdhury\u00a0F, Tappuni\u00a0A, Bombardieri\u00a0M (2021) Biological therapy in primary Sjogren\u2019s syndrome: effect on salivary gland function and inflammation. Front Med 8:707104. https:\/\/doi.org\/10.3389\/fmed.2021.707104","journal-title":"Front Med"},{"key":"1249_CR8","unstructured":"Christ L, Seitz L, Buetikofer L et al (2020) A proof of concept study to assess the efficacy of tocilizumab in combination with ultra-short glucocorticoid administration to treat newly diagnosed giant cell Arteritis\u2014a\u00a024 week analysis [abstract]. Arthritis & rheumatology 72 (suppl 10). https:\/\/acrabstracts.org\/abstract\/a-proof-of-concept-study-to-assess-the-efficacy-of-tocilizumab-in-combination-with-ultra-short-glucocorticoid-administration-to-treat-newly-diagnosed-giant-cell-arteritis-a-24-week-analysis\/. Zugegriffen: 10. Nov. 2020"},{"key":"1249_CR9","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/art.41776","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung\u00a0SA, Gorelik\u00a0M, Langford\u00a0CA et\u00a0al (2021) 2021 American College of Rheumatology\/Vasculitis foundation guideline for the management of polyarteritis nodosa. Arthritis Rheumatol 73:1384\u20131393. https:\/\/doi.org\/10.1002\/art.41776","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR10","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung\u00a0SA, Langford\u00a0CA, Maz\u00a0M et al (2021) 2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated Vasculitis. Arthritis Rheumatol 73:1366\u20131383. https:\/\/doi.org\/10.1002\/art.41773","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2021-eular.1915","volume":"80","author":"M Cid","year":"2021","unstructured":"Cid\u00a0M, Unizony\u00a0S, Pupin\u00a0L et al (2021) Mavrilimumab (anti GM-CSF-receptor A monoclonal antibody) reduces risk of flare and increases sustained remission in a\u00a0phase 2 trials of patients with giant cell arteritis (Abstract). Ann Rheum Dis 80:31","journal-title":"Ann Rheum Dis"},{"key":"1249_CR12","doi-asserted-by":"publisher","first-page":"102784","DOI":"10.1016\/j.autrev.2021.102784","volume":"20","author":"E Conticini","year":"2021","unstructured":"Conticini\u00a0E, Sota\u00a0J, Falsetti\u00a0P et\u00a0al (2021) Biologic drugs in the treatment of polyarteritis nodosa and deficit of adenosine deaminase 2: a narrative review. Autoimmun Rev 20:102784. https:\/\/doi.org\/10.1016\/j.autrev.2021.102784","journal-title":"Autoimmun Rev"},{"key":"1249_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","volume":"48","author":"R Conway","year":"2018","unstructured":"Conway\u00a0R, O\u2019neill\u00a0L, Gallagher\u00a0P et al (2018) Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial. Semin Arthritis Rheum 48:523\u2013528. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.04.004","journal-title":"Semin Arthritis Rheum"},{"key":"1249_CR14","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler\u00a0O, Highland\u00a0KB, Gahlemann\u00a0M et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N\u00a0Engl J Med 380:2518\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1903076","journal-title":"N Engl J Med"},{"key":"1249_CR15","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Alunno\u00a0A et\u00a0al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736\u2013745. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"1249_CR16","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty\u00a0KR, Wells\u00a0AU, Cottin\u00a0V et\u00a0al (2019) Nintedanib in progressive fibrosing interstitial lung diseases. N\u00a0Engl J Med 381:1718\u20131727. https:\/\/doi.org\/10.1056\/NEJMoa1908681","journal-title":"N Engl J Med"},{"key":"1249_CR17","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie\u00a0R, Petri\u00a0M, Zamani\u00a0O et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a\u00a0monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918\u20133930. https:\/\/doi.org\/10.1002\/art.30613","journal-title":"Arthritis Rheum"},{"key":"1249_CR18","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie\u00a0R, Rovin\u00a0BH, Houssiau\u00a0F et al (2020) Two-year, randomized, controlled trial of Belimumab in lupus nephritis. N\u00a0Engl J Med 383:1117\u20131128. https:\/\/doi.org\/10.1056\/NEJMoa2001180","journal-title":"N Engl J Med"},{"key":"1249_CR19","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.autrev.2019.06.008","volume":"18","author":"M Galli","year":"2019","unstructured":"Galli\u00a0M, Monti\u00a0G, Marson\u00a0P et al (2019) Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. Autoimmun Rev 18:778\u2013785. https:\/\/doi.org\/10.1016\/j.autrev.2019.06.008","journal-title":"Autoimmun Rev"},{"key":"1249_CR20","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin\u00a0L, Pagnoux\u00a0C, Karras\u00a0A et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N\u00a0Engl J Med 371:1771\u20131780. https:\/\/doi.org\/10.1056\/NEJMoa1404231","journal-title":"N Engl J Med"},{"key":"1249_CR21","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","volume":"9","author":"VP Guntur","year":"2021","unstructured":"Guntur\u00a0VP, Manka\u00a0LA, Denson\u00a0JL et al (2021) Benralizumab as a\u00a0steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J\u00a0Allergy Clin Immunol Pract 9:1186\u20131193.e1. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.054","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1249_CR22","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi\u00a0G, Christensen\u00a0R, Bang\u00a0D et\u00a0al (2018) 2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome. Ann Rheum Dis 77:808\u2013818. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213225","journal-title":"Ann Rheum Dis"},{"key":"1249_CR23","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s00393-020-00828-w","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich\u00a0B (2020) So behandle ich: ANCA-assoziierte Vaskulitiden nach Erreichen einer Remission. Z\u00a0Rheumatol 79:696\u2013701. https:\/\/doi.org\/10.1007\/s00393-020-00828-w","journal-title":"Z Rheumatol"},{"key":"1249_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich\u00a0B, Agueda\u00a0A, Monti\u00a0S et\u00a0al (2020) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79:19\u201330. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215672","journal-title":"Ann Rheum Dis"},{"key":"1249_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11926-020-00964-x","volume":"22","author":"B Hellmich","year":"2020","unstructured":"Hellmich\u00a0B, Agueda\u00a0AF, Monti\u00a0S et al (2020) Treatment of giant cell Arteritis and Takayasu Arteritis-current and future. Curr Rheumatol Rep 22:84. https:\/\/doi.org\/10.1007\/s11926-020-00964-x","journal-title":"Curr Rheumatol Rep"},{"key":"1249_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00686-z","author":"B Hellmich","year":"2021","unstructured":"Hellmich\u00a0B, Buttgereit\u00a0F (2021) GCA management guidelines\u2013vive la diff\u00e9rence? Nat Rev Rheumatol. https:\/\/doi.org\/10.1038\/s41584-021-00686-z","journal-title":"Nat Rev Rheumatol"},{"key":"1249_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1196\/annals.1361.053","volume":"1051","author":"B Hellmich","year":"2005","unstructured":"Hellmich\u00a0B, Csernok\u00a0E, Gross\u00a0WL (2005) Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann NY Acad Sci 1051:121\u2013131. https:\/\/doi.org\/10.1196\/annals.1361.053","journal-title":"Ann NY Acad Sci"},{"key":"1249_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11560-011-0607-6","volume":"7","author":"B Hellmich","year":"2012","unstructured":"Hellmich\u00a0B, De Groot\u00a0K (2012) Kryoglobulin\u00e4mische Vaskulitis. Nephrologe 7:209\u2013221","journal-title":"Nephrologe"},{"key":"1249_CR29","first-page":"S69","volume":"21","author":"B Hellmich","year":"2003","unstructured":"Hellmich\u00a0B, Ehlers\u00a0S, Csernok\u00a0E et al (2003) Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 21:S69\u2013S77","journal-title":"Clin Exp Rheumatol"},{"key":"1249_CR30","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/art.40802","volume":"71","author":"D Jayne","year":"2019","unstructured":"Jayne\u00a0D, Blockmans\u00a0D, Luqmani\u00a0R et al (2019) Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study. Arthritis Rheumatol 71:952\u2013963. https:\/\/doi.org\/10.1002\/art.40802","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne\u00a0DRW, Merkel\u00a0PA, Schall\u00a0TJ et al (2021) Avacopan for the treatment of ANCA-associated vasculitis. N\u00a0Engl J Med 384:599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2023386","journal-title":"N Engl J Med"},{"key":"1249_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones\u00a0RB, Tervaert\u00a0JW, Hauser\u00a0T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N\u00a0Engl J Med 363:211\u2013220","journal-title":"N Engl J Med"},{"key":"1249_CR33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","volume":"77","author":"D Khanna","year":"2018","unstructured":"Khanna\u00a0D, Denton\u00a0CP, Lin\u00a0CJF et al (2018) Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a\u00a0phase II randomised controlled trial (faSScinate). Ann Rheum Dis 77:212\u2013220. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211682","journal-title":"Ann Rheum Dis"},{"key":"1249_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/art.41055","volume":"72","author":"D Khanna","year":"2020","unstructured":"Khanna\u00a0D, Spino\u00a0C, Johnson\u00a0S et al (2020) Abatacept in early diffuse cutaneous systemic sclerosis: results of a\u00a0phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheumatol 72:125\u2013136. https:\/\/doi.org\/10.1002\/art.41055","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford\u00a0CA, Cuthbertson\u00a0D, Ytterberg\u00a0SR et al (2017) A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 69:837\u2013845. https:\/\/doi.org\/10.1002\/art.40044","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR36","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","volume":"73","author":"CA Langford","year":"2014","unstructured":"Langford\u00a0CA, Monach\u00a0PA, Specks\u00a0U et al (2014) An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener\u2019s). Ann Rheum Dis 73:1376\u20131379. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204164","journal-title":"Ann Rheum Dis"},{"key":"1249_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/acr2.11189","volume":"3","author":"YC Lin","year":"2021","unstructured":"Lin\u00a0YC, Kalot\u00a0MA, Husainat\u00a0NM et\u00a0al (2021) Polyarteritis nodosa: a systematic review of test accuracy and benefits and harms of common treatments. ACR Open Rheumatol 3:91\u2013100. https:\/\/doi.org\/10.1002\/acr2.11189","journal-title":"ACR Open Rheumatol"},{"key":"1249_CR38","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","volume":"126","author":"LA Manka","year":"2021","unstructured":"Manka\u00a0LA, Guntur\u00a0VP, Denson\u00a0JL et\u00a0al (2021) Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann Allergy Asthma Immunol 126:696\u2013701.e691. https:\/\/doi.org\/10.1016\/j.anai.2021.01.035","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1249_CR39","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/acr.24200","volume":"73","author":"MA Matza","year":"2021","unstructured":"Matza\u00a0MA, Fernandes\u00a0AD, Stone\u00a0JH et\u00a0al (2021) Ustekinumab for the treatment of giant cell Arteritis. Arthritis Care Res 73:893\u2013897. https:\/\/doi.org\/10.1002\/acr.24200","journal-title":"Arthritis Care Res"},{"key":"1249_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/art.41774","author":"M Maz","year":"2021","unstructured":"Maz\u00a0M, Chung\u00a0SA, Abril\u00a0A et\u00a0al (2021) 2021 American college of rheumatology\/vasculitis foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41774","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR41","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/ndt\/gfy075","volume":"33","author":"SP Mcadoo","year":"2018","unstructured":"Mcadoo\u00a0SP, Medjeral-Thomas\u00a0N, Gopaluni\u00a0S et al (2018) Long-term follow-up of a\u00a0combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant 33:899. https:\/\/doi.org\/10.1093\/ndt\/gfy075","journal-title":"Nephrol Dial Transplant"},{"key":"1249_CR42","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1093\/rheumatology\/keab046","volume":"60","author":"VG Menditto","year":"2021","unstructured":"Menditto\u00a0VG, Rossetti\u00a0G, Olivari\u00a0D et\u00a0al (2021) Rituximab for eosinophilic granulomatosis with polyangiitis: a\u00a0systematic review of observational studies. Rheumatology 60:1640\u20131650. https:\/\/doi.org\/10.1093\/rheumatology\/keab046","journal-title":"Rheumatology"},{"key":"1249_CR43","doi-asserted-by":"publisher","first-page":"e001003","DOI":"10.1136\/rmdopen-2019-001003","volume":"5","author":"S Monti","year":"2019","unstructured":"Monti\u00a0S, Agueda\u00a0AF, Luqmani\u00a0RA et\u00a0al (2019) Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open 5:e1003. https:\/\/doi.org\/10.1136\/rmdopen-2019-001003","journal-title":"RMD Open"},{"key":"1249_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05698-4","author":"M Moradzadeh","year":"2021","unstructured":"Moradzadeh\u00a0M, Aghaei\u00a0M, Mehrbakhsh\u00a0Z et al (2021) Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-021-05698-4","journal-title":"Clin Rheumatol"},{"key":"1249_CR45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand\u00a0EF, Furie\u00a0R, Tanaka\u00a0Y et\u00a0al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N\u00a0Engl J Med 382:211\u2013221. https:\/\/doi.org\/10.1056\/NEJMoa1912196","journal-title":"N Engl J Med"},{"key":"1249_CR46","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","volume":"77","author":"Y Nakaoka","year":"2018","unstructured":"Nakaoka\u00a0Y, Isobe\u00a0M, Takei\u00a0S et al (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a\u00a0randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77:348\u2013354. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211878","journal-title":"Ann Rheum Dis"},{"key":"1249_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez630","author":"Y Nakaoka","year":"2020","unstructured":"Nakaoka\u00a0Y, Isobe\u00a0M, Tanaka\u00a0Y et al (2020) Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/kez630","journal-title":"Rheumatology"},{"key":"1249_CR48","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra\u00a0SV, Guzman\u00a0RM, Gallacher\u00a0AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a\u00a0randomised, placebo-controlled, phase 3 trial. Lancet 377:721\u2013731. https:\/\/doi.org\/10.1016\/S0140-6736(10)61354-2","journal-title":"Lancet"},{"key":"1249_CR49","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis\u00a0CV, Reed\u00a0AM, Aggarwal\u00a0R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a\u00a0randomized, placebo-phase trial. Arthritis Rheum 65:314\u2013324. https:\/\/doi.org\/10.1002\/art.37754","journal-title":"Arthritis Rheum"},{"key":"1249_CR50","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/rheumatology\/key288","volume":"58","author":"RJ Pepper","year":"2019","unstructured":"Pepper\u00a0RJ, Mcadoo\u00a0SP, Moran\u00a0SM et al (2019) A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 58:260\u2013268. https:\/\/doi.org\/10.1093\/rheumatology\/key288","journal-title":"Rheumatology"},{"key":"1249_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez511","author":"S Saito","year":"2019","unstructured":"Saito\u00a0S, Okuyama\u00a0A, Okada\u00a0Y et al (2019) Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a\u00a0prospective, single-centre, open study. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/kez511","journal-title":"Rheumatology"},{"key":"1249_CR52","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.autrev.2018.12.002","volume":"18","author":"C Salvarani","year":"2019","unstructured":"Salvarani\u00a0C, Brown\u00a0RD Jr., Muratore\u00a0F et\u00a0al (2019) Rituximab therapy for primary central nervous system vasculitis: a 6\u00a0patient experience and review of the literature. Autoimmun Rev 18:399\u2013405. https:\/\/doi.org\/10.1016\/j.autrev.2018.12.002","journal-title":"Autoimmun Rev"},{"issue":"Suppl 103","key":"1249_CR53","first-page":"176","volume":"35","author":"M Samson","year":"2017","unstructured":"Samson\u00a0M, Puechal\u00a0X, Mouthon\u00a0L et al (2017) Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. Clin Exp Rheumatol 35(Suppl 103):176\u2013184","journal-title":"Clin Exp Rheumatol"},{"key":"1249_CR54","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00393-020-00893-1","volume":"79","author":"JH Schirmer","year":"2020","unstructured":"Schirmer\u00a0JH, Aries\u00a0PM, Balzer\u00a0K et\u00a0al (2020) S2k Leitlinie Management der Gro\u00dfgef\u00e4\u00dfvaskulitiden. Z\u00a0Rheumatol 79:67\u201395. https:\/\/doi.org\/10.1007\/s00393-020-00893-1","journal-title":"Z Rheumatol"},{"key":"1249_CR55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00393-017-0394-1","volume":"76","author":"JH Schirmer","year":"2017","unstructured":"Schirmer\u00a0JH, Aries\u00a0PM, De Groot\u00a0K et al (2017) S1 Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden. Z\u00a0Rheumatol 76:77\u2013104. https:\/\/doi.org\/10.1007\/s00393-017-0394-1","journal-title":"Z Rheumatol"},{"key":"1249_CR56","doi-asserted-by":"crossref","unstructured":"Smith R, Jayne D, Merkel P (2019) A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease [abstract]. Arthritis & rheumatology 71. https:\/\/acrabstracts.org\/abstract\/a-randomized-controlled-trial-of-rituximab-versus-azathioprine-after-induction-of-remission-with-rituximab-for-patients-with-anca-associated-vasculitis-and-relapsing-disease\/. Zugegriffen: 6. Jan. 2020","DOI":"10.1093\/ndt\/gfaa146.LB004"},{"key":"1249_CR57","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","volume":"79","author":"RM Smith","year":"2020","unstructured":"Smith\u00a0RM, Jones\u00a0RB, Specks\u00a0U et al (2020) Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 79:1243\u20131249. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216863","journal-title":"Ann Rheum Dis"},{"key":"1249_CR58","doi-asserted-by":"publisher","first-page":"E328","DOI":"10.1016\/S2665-9913(21)00038-2","volume":"3","author":"J Stone","year":"2021","unstructured":"Stone\u00a0J, Han\u00a0J, Aringer\u00a0M et al (2021) Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatol 3:E328\u2013E336","journal-title":"Lancet Rheumatol"},{"key":"1249_CR59","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone\u00a0JH, Merkel\u00a0PA, Spiera\u00a0R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N\u00a0Engl J Med 363:221\u2013232. https:\/\/doi.org\/10.1056\/NEJMoa0909905","journal-title":"N Engl J Med"},{"key":"1249_CR60","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone\u00a0JH, Tuckwell\u00a0K, Dimonaco\u00a0S et al (2017) Trial of tocilizumab in giant-cell arteritis. N\u00a0Engl J Med 377:317\u2013328. https:\/\/doi.org\/10.1056\/NEJMoa1613849","journal-title":"N Engl J Med"},{"key":"1249_CR61","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/art.40876","volume":"71","author":"JH Stone","year":"2019","unstructured":"Stone\u00a0JH, Tuckwell\u00a0K, Dimonaco\u00a0S et al (2019) Glucocorticoid dosages and acute-phase reactant levels at giant cell Arteritis flare in a\u00a0randomized trial of tocilizumab. Arthritis Rheumatol 71:1329\u20131338. https:\/\/doi.org\/10.1002\/art.40876","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR62","doi-asserted-by":"publisher","first-page":"e000905","DOI":"10.1136\/rmdopen-2019-000905","volume":"5","author":"V Teixeira","year":"2019","unstructured":"Teixeira\u00a0V, Mohammad\u00a0AJ, Jones\u00a0RB et\u00a0al (2019) Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open 5:e905. https:\/\/doi.org\/10.1136\/rmdopen-2019-000905","journal-title":"RMD Open"},{"key":"1249_CR63","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","volume":"77","author":"B Terrier","year":"2018","unstructured":"Terrier\u00a0B, Pagnoux\u00a0C, Perrodeau\u00a0E et al (2018) Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 77:1150\u20131156. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212768","journal-title":"Ann Rheum Dis"},{"key":"1249_CR64","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"The Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","unstructured":"The Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N\u00a0Engl J Med 352:351\u2013361","journal-title":"N Engl J Med"},{"key":"1249_CR65","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1136\/annrheumdis-2021-eular.2221","volume":"80","author":"S Unizony","year":"2021","unstructured":"Unizony\u00a0S, Cid\u00a0M, Brouwer\u00a0E et\u00a0al (2021) Utility of CRP and ESR in the diagnosis of gicnt cell arteritis relapse in a\u00a0phase 2 trial of mavrilimumab. Ann Rheum Dis 80:1211","journal-title":"Ann Rheum Dis"},{"key":"1249_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220347","author":"SH Unizony","year":"2021","unstructured":"Unizony\u00a0SH, Bao\u00a0M, Han\u00a0J et\u00a0al (2021) Treatment failure in giant cell arteritis. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220347","journal-title":"Ann Rheum Dis"},{"key":"1249_CR67","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger\u00a0PM, Adler\u00a0S, Kuchen\u00a0S et al (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a\u00a0phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387:1921\u20131927. https:\/\/doi.org\/10.1016\/S0140-6736(16)00560-2","journal-title":"Lancet"},{"key":"1249_CR68","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace\u00a0DJ, Furie\u00a0RA, Tanaka\u00a0Y et al (2018) Baricitinib for systemic lupus erythematosus: a\u00a0double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392:222\u2013231. https:\/\/doi.org\/10.1016\/S0140-6736(18)31363-1","journal-title":"Lancet"},{"key":"1249_CR69","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh\u00a0M, Merkel\u00a0PA, Peh\u00a0CA et al (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N\u00a0Engl J Med 382:622\u2013631. https:\/\/doi.org\/10.1056\/NEJMoa1803537","journal-title":"N Engl J Med"},{"key":"1249_CR70","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler\u00a0ME, Akuthota\u00a0P, Jayne\u00a0D et\u00a0al (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N\u00a0Engl J Med 376:1921\u20131932. https:\/\/doi.org\/10.1056\/NEJMoa1702079","journal-title":"N Engl J Med"},{"key":"1249_CR71","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates\u00a0M, Watts\u00a0RA, Bajema\u00a0IM et al (2016) EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583\u20131594. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209133","journal-title":"Ann Rheum Dis"},{"key":"1249_CR72","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","volume":"59","author":"H You","year":"2020","unstructured":"You\u00a0H, Xu\u00a0D, Zhao\u00a0J et\u00a0al (2020) JAK inhibitors: prospects in connective tissue diseases. Clin Rev Allergy Immunol 59:334\u2013351. https:\/\/doi.org\/10.1007\/s12016-020-08786-6","journal-title":"Clin Rev Allergy Immunol"},{"key":"1249_CR73","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/annrheumdis-2012-202857","volume":"73","author":"M Zong","year":"2014","unstructured":"Zong\u00a0M, Dorph\u00a0C, Dastmalchi\u00a0M et al (2014) Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a\u00a0mechanistic study with 12\u00a0months follow-up. Ann Rheum Dis 73:913\u2013920. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202857","journal-title":"Ann Rheum Dis"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01249-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-01249-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01249-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T11:06:48Z","timestamp":1643886408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-01249-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1249"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-01249-w","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]},"assertion":[{"value":"16 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0Hellmich: Honorare f\u00fcr Beratung von Boehringer-Ingelheim, GSK, InflaRx, Roche und Vifor, Honorare f\u00fcr Referentent\u00e4tigkeit von AbbVie, BMS, Celgene, Chugai, GSK, MSD, Novartis, Pfizer, UCB, Roche; ehrenamtliche nicht verg\u00fctete Koordination von Leitlinien zu Gro\u00dfgef\u00e4\u00dfvaskulitiden: European Alliance of Associations for Rheumatology (EULAR), Deutsche Gesellschaft f\u00fcr Rheumatologie (DGRh). J.C.\u00a0Henes Honorare f\u00fcr Beratungs- und Vortragst\u00e4tigkeiten von Abbvie, Boehringer-Ingelheim, GSK, Roche, MSD, Novartis, Pfizer, SOBI, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}